Melanotan-2 Bloodwork Guide: What Labs to Track (2026)
Melanotan-2 bloodwork guide: track cortisol, liver enzymes, kidney function, and lipids with optimal ranges and testing timeline.
Melanotan-2 Bloodwork Guide: What to Track and Why
Melanotan-2 is a synthetic cyclic analog of alpha-MSH that activates melanocortin receptors — primarily MC1R for skin pigmentation, but also MC3R, MC4R, and MC5R, which influence appetite, sexual function, and hormonal signaling. It is not a simple tanning peptide. It is a systemic melanocortin agonist with effects across multiple organ systems.
This makes safety monitoring more important for MT-2 than for many other research peptides. Unlike BPC-157 or TB-500, where the primary risk is "it does not work," MT-2 has documented side effects including nausea, blood pressure changes, darkening of moles, and hormonal shifts. Bloodwork and dermatological monitoring are not optional extras — they are the responsible minimum.
The Testing Timeline
Baseline (before starting): Run blood panels and get a dermatological skin exam 1-2 weeks before your first dose.
Mid-protocol check (week 4-6): Retest hormonal markers, CMP, and blood pressure. Get a skin check if any moles have visibly changed.
Post-protocol (2-4 weeks after finishing): Full retest. MT-2's effects on pigmentation can persist for months, but hormonal and cardiovascular markers should normalize relatively quickly.
Ongoing during protocol: Home blood pressure monitoring 2-3 times per week. Monthly self-skin checks using the ABCDE criteria (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolution/change).
Minimum panel for MT-2: CMP (liver + kidney), lipid panel, CBC, blood pressure log. Add cortisol and a dermatological exam. Details below.
Biomarkers at a Glance
Click any bar to jump to the full breakdown.
Tier 1: Hormonal Markers
MT-2 is a melanocortin receptor agonist. The melanocortin system interfaces with the hypothalamic-pituitary-adrenal (HPA) axis, which means hormonal effects are expected, not incidental.
Alpha-MSH (Alpha-Melanocyte-Stimulating Hormone)
What it measures: Your body's endogenous melanocortin signaling. Alpha-MSH is the natural hormone that MT-2 mimics.
Normal range: 10-40 pg/mL (varies by assay).
Why it matters for MT-2: Baseline alpha-MSH levels tell you where your natural melanocortin signaling sits. Exogenous MT-2 will activate the same receptors. Individuals with naturally higher alpha-MSH may be more sensitive to MT-2's effects and may need lower doses.
How to test: Specialty lab order (plasma alpha-MSH). Not available through all standard lab panels — may require a functional or endocrine medicine provider.
Cortisol (Morning)
What it measures: Your primary stress hormone, produced by the adrenal glands under HPA axis control. The melanocortin system (MC2R specifically) interfaces with adrenal function.
Why it matters for MT-2: While MT-2 primarily targets MC1R, it has affinity for other melanocortin receptors. Tracking cortisol ensures the HPA axis is not being significantly perturbed. Morning cortisol is the most standardized measurement.
Top Melanotan II Vendors
Ranked by price, COA availability, and reputation
Tier 2: Cardiovascular Markers
MT-2 can cause transient blood pressure elevation and cardiovascular symptoms. These markers establish your cardiovascular safety baseline.
Blood Pressure Monitoring
What it measures: Systolic and diastolic arterial pressure. Not a blood test — this is measured with a cuff at home.
Optimal range: Below 120/80 mmHg. Stage 1 hypertension begins at 130/80.
Why it matters for MT-2: Case reports document blood pressure increases, flushing, and sympathomimetic-like symptoms with MT-2 use. Regular home monitoring catches trends before they become problems.
How to track: Use a home blood pressure monitor. Measure 2-3 times per week at the same time of day (morning, before caffeine). Log the numbers.
Lipid Panel
What it measures: Total cholesterol, LDL, HDL, and triglycerides.
Why track it for MT-2: Melanocortin signaling through MC4R influences energy metabolism and lipid handling. Tracking lipids gives you a broader metabolic safety picture.
Tier 3: Renal and Liver Function
Any exogenous compound requires organ safety monitoring. MT-2's systemic activity makes this particularly important.
Comprehensive Metabolic Panel (CMP)
The CMP covers 14 markers in one test, including the liver and kidney markers most relevant to MT-2 safety.
Liver Enzymes (ALT, AST, GGT):
Optimal ALT is below 25 U/L. Standard lab ranges go up to 40, but that "normal" range includes unhealthy people. Track ALT at baseline and post-protocol to confirm no hepatic stress.
Kidney Function (BUN, Creatinine, eGFR):
Why track kidney function for MT-2: There is at least one documented case of MT-2 use resulting in rhabdomyolysis and renal dysfunction. While this appears rare and may have been dose-related, kidney function monitoring is a reasonable safety measure.
Electrolytes
Included in the CMP. Sodium, potassium, chloride, bicarbonate. MT-2's effects on appetite and fluid intake could theoretically shift electrolyte balance over longer protocols.
Tier 4: Dermatological Monitoring
This is unique to MT-2 and arguably the most important monitoring category. MT-2 stimulates melanocytes — the cells responsible for pigmentation. This includes melanocytes in moles.
Baseline Mole Mapping
What it is: A comprehensive dermatological exam where every mole, freckle, and pigmented lesion is documented with photographs. This gives you a reference point to detect any changes.
Why it matters: MT-2 can darken existing moles, make previously invisible moles visible, and theoretically stimulate melanocyte activity in atypical moles. Case reports have associated MT-2 use with melanoma diagnosis, though causality is not established.
How to get it: Schedule with a dermatologist. Ask specifically for full-body mole mapping. Some dermatology clinics offer total-body photography.
Monthly Self-Checks
Between dermatologist visits, perform monthly self-skin checks using the ABCDE criteria:
- A — Asymmetry: one half does not match the other
- B — Border: edges are irregular, ragged, or blurred
- C — Color: uneven color, multiple shades
- D — Diameter: larger than 6mm (pencil eraser size)
- E — Evolution: any change in size, shape, color, or symptoms
If any mole meets one or more of these criteria, see a dermatologist immediately. Do not wait for your scheduled check.
Follow-Up Dermatological Exams
Every 3-6 months during MT-2 use, and at least once 3 months after stopping. Pigmentation changes from MT-2 can persist for months after discontinuation.
How to Order Labs
- Direct-to-consumer labs: HealthLabs.com lets you order bloodwork without a prescription or insurance. Order online, walk into any of 4,500+ draw sites, and get results in 1-2 business days.
- Alpha-MSH: Specialty test — may require an endocrinologist or functional medicine provider to order.
- Dermatological exam: Schedule with any board-certified dermatologist. Mention that you want mole mapping specifically.
- Blood pressure monitor: Purchase a validated home unit ($30-60). Measure consistently at the same time of day.
Budget-conscious approach:
- CMP ($15-25 — covers liver, kidney, electrolytes)
- CBC ($10-20)
- Lipid panel ($15-30)
- Morning cortisol ($20-40)
- Home blood pressure monitor ($30-60, one-time purchase)
- Dermatological exam (check insurance coverage — often covered as preventive)
Putting It All Together: Sample Protocol
Week -2 to -1 (Baseline): Run CMP, CBC, lipid panel, cortisol. Schedule dermatological mole mapping. Begin blood pressure logging.
Weeks 1-4 (Loading/titration): Track blood pressure 2-3 times/week. Monitor for nausea, flushing, headaches. Monthly self-skin check. Journal subjective effects.
Week 4-6 (Mid-protocol): Retest CMP and cortisol. Review blood pressure logs for any upward trend. Self-skin check — note any mole changes.
Week 8-12 (Post-protocol or ongoing maintenance): Full retest of all baseline labs. Dermatological follow-up exam. Compare mole mapping to baseline. Review blood pressure trend over the entire protocol.
What to do with results: If liver enzymes rose significantly, blood pressure trended up, or moles changed, these are signals to stop or reduce dosing and consult a healthcare provider. If markers stayed stable and skin exams are clean, you have objective evidence the protocol was tolerated safely.
Related Reading
-
Melanotan 2 Dosing Guide — protocols, loading and maintenance phases
-
BPC-157 Bloodwork Guide — the gold standard biomarker reference for healing peptides
-
TB-500 Bloodwork Guide — inflammatory and cardiac markers
-
SS-31 Bloodwork Guide — mitochondrial and oxidative stress markers
-
Melanotan-2 Reconstitution Guide — how to mix and store MT-2
-
BPC-157 Reconstitution Guide — mixing reference for the most popular peptide
-
Epitalon Benefits — another peptide with systemic effects worth monitoring
References
- Wessells, H., et al. (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research, 12(Suppl 4), S74-S79. PMID: 11035391
- Hjuler, K.F., et al. (2014). Melanoma associated with the use of melanotan-II. Dermatology, 228(1), 34-36. PMID: 24355990
- Devlin, J., et al. (2012). Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology, 50(10), 1054. PMID: 23121206
- Nelson, M.E., et al. (2021). Melanotan II user experience: A qualitative study of online discussion forums. Performance Enhancement & Health, 9(3-4), 100203. PMID: 34464955
- Brennan, R., et al. (2017). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. BMJ Open, 4(2), e004573. PMID: 28266027
This guide is for educational and informational purposes only. It is not medical advice. Melanotan-2 is sold as a research compound and is not FDA-approved for human use. MT-2 carries specific risks including changes to moles and pigmented lesions, blood pressure elevation, nausea, and hormonal effects. Dermatological monitoring is strongly recommended during and after use. The biomarker ranges described here reflect optimization targets — they are not diagnostic criteria. Lab results should be interpreted by a qualified healthcare provider. The Peptide Catalog is not responsible for medical decisions made based on information presented here. HealthLabs.com links are affiliate links — we may earn a commission at no additional cost to you.